NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.58 0.00 (0.00 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$4.44Now: $4.58▼$4.7450-Day Range$3.93MA: $4.40▼$4.7052-Week Range$2.50Now: $4.58▼$5.89Volume281,431 shsAverage Volume790,697 shsMarket Capitalization$197.54 millionP/E RatioN/ADividend YieldN/ABeta1.54 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.50, Paratek Pharmaceuticals has a potential upside of 303.9% from its current price of $4.58.Amount of Analyst CoverageParatek Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesParatek Pharmaceuticals has received 413 “outperform” votes. (Add your “outperform” vote.)Underperform VotesParatek Pharmaceuticals has received 371 “underperform” votes. (Add your “underperform” vote.)Community SentimentParatek Pharmaceuticals has received 52.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote “Outperform” if you believe PRTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $154,510.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions43.41% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($1.95) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone617-807-6600Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio4.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.54 million Price / Sales11.94 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-3.85Profitability EPS (Most Recent Fiscal Year)($3.93) Net Income$-128,790,000.00 Net Margins-528.28% Return on Equity-5,327.73% Return on Assets-47.65%Miscellaneous Employees101 Outstanding Shares43,132,000Market Cap$197.54 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:PRTK Rates by TradingView Receive PRTK News and Ratings via Email Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions How has Paratek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRTK shares have increased by 17.7% and is now trading at $4.58. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals. When is Paratek Pharmaceuticals' next earnings date? Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Paratek Pharmaceuticals. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.14. The specialty pharmaceutical company earned $7.92 million during the quarter, compared to analysts' expectations of $7.75 million. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 528.28%. View Paratek Pharmaceuticals' earnings history. What guidance has Paratek Pharmaceuticals issued on next quarter's earnings? Paratek Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $81.12 million. What price target have analysts set for PRTK? 6 Wall Street analysts have issued 12 month target prices for Paratek Pharmaceuticals' stock. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $18.50 in the next twelve months. This suggests a possible upside of 303.9% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals. Has Paratek Pharmaceuticals been receiving favorable news coverage? Press coverage about PRTK stock has trended very negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutParatek Pharmaceuticals. Who are some of Paratek Pharmaceuticals' key competitors? Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), EXACT Sciences (EXAS), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). Who are Paratek Pharmaceuticals' key executives? Paratek Pharmaceuticals' management team includes the following people: Mr. Michael F. Bigham CPA, MBA, Exec. Chairman (Age 62, Pay $881.68k)Dr. Evan Loh, CEO & Director (Age 61, Pay $906.9k)Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 53, Pay $672.21k)Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 58, Pay $586k)Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 45) What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." Who are Paratek Pharmaceuticals' major shareholders? Paratek Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.68%), Rock Springs Capital Management LP (3.54%), General American Investors Co. Inc. (1.89%), Granahan Investment Management Inc. MA (1.66%), State Street Corp (1.54%) and Water Island Capital LLC (0.83%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals. Which institutional investors are selling Paratek Pharmaceuticals stock? PRTK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Arbiter Partners Capital Management LLC, Water Island Capital LLC, Morgan Stanley, State Street Corp, Parametric Portfolio Associates LLC, and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals. Which institutional investors are buying Paratek Pharmaceuticals stock? PRTK stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Balyasny Asset Management LLC, General American Investors Co. Inc., Nuveen Asset Management LLC, BlackRock Inc., Trellus Management Company LLC, Connor Clark & Lunn Investment Management Ltd., and HighTower Advisors LLC. View insider buying and selling activity for Paratek Pharmaceuticals. How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $4.58. How big of a company is Paratek Pharmaceuticals? Paratek Pharmaceuticals has a market capitalization of $197.54 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. What is Paratek Pharmaceuticals' official website? The official website for Paratek Pharmaceuticals is www.paratekpharma.com. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
